Download MendeleyDiscovery of Gut-Restricted PRMT5 Inhibitors to Intercept Colorectal Cancer in Patients with Genetic Loss of Tumor Suppressor Adenomatous Polyposis Coli.
Hulpia, F., Schepens, W., Lepri, S., Nicolai, J., Jiang, Z., Boj, S.F., Bush, T.L., Carvalho, M.A., Chen, F., Chu, G., Clancy, K.W., Etwebi, Z., Everaerts, M., Fan, Y., Fernandez Candelaria, F.O., Francis, A., Hixon, M.S., Jardi, F., Jin, S., Larin, E.M., Last, S., Leenaerts, J.E., Li, S., Liddane, A.G., Lutter, F.H., Lv, D., Mattson, B., Milligan, C.M., Patrick, A.N., Patwardhan, G.A., Perez-Benito, L., Pieters, S., Renders, E., Retzbach, E., Smith-Monroy, C., Silva, J., Silva, M., Sterckx, H., Ten Hag, G., Thate, C., Van Brandt, S., Verissimo, C.S., Verniest, G., Vesely, E., Vetrano, I., Vinken, P., Wang, Y., Wong, V., Yao, X., Yang, J., Zijlmans, R., Bachman, K.E., Pocalyko, D., Jimenez, J.M., Gaffney, D., Thuring, J.W.(2025) J Med Chem
- PubMed: 40857667
- DOI: https://doi.org/10.1021/acs.jmedchem.5c00830
- Primary Citation of Related Structures:
9PCA - PubMed Abstract:
Loss of the functional Adenomatous Polyposis Coli ( APC -LOF) tumor suppressor gene represents the disease-initiating event in most colorectal cancer (CRC) cases. A newly identified dependency between PRMT5 and APC -LOF suggests that inhibiting PRMT5 may help intercept CRC. To circumvent hematological toxicities associated with orally bioavailable first-generation PRMT5 inhibitors, we aimed to limit systemic exposure after oral administration. We describe our efforts, challenges, and compound evaluation workflow resulting in gut-restricted PRMT5 inhibitors. A two-pronged approach was envisioned, consisting of (1) minimizing passive absorption, and (2) maximizing systemic clearance by incorporation of a metabolic "soft spot". This resulted in 9 and 18 , displaying low absorption in preclinical species and high first-pass extraction mediated by aldehyde oxidase. 9 and 18 demonstrated in vivo colon pharmacodynamics without signs of systemic on-target toxicity, confirming gut-restriction. Administering 9 to dextran sodium sulfate (DSS)-treated polyp-bearing Apc Min/+ mice significantly reduced polyp number, indicating local treatment efficacy.
- Global Discovery Chemistry, Therapeutics Discovery (TD), DPDS, Janssen Pharmaceutica NV, Johnson & Johnson Innovative Medicine, Beerse B-2340, Belgium.
Organizational Affiliation:
